It was recently announced that an amendment to the manufacturing process of 'Lanoxin' (Burroughs Wellcome) tablets had resulted in an increase in the amount of digoxin absorbed from the tablets (British Medical Journal, I972; Lancet, I972) . This increase in the biological availability of the drug was thought to be approximately twofold. The increased biological availability of Lanoxin tablets was associated with a faster rate of release of the drug into solution as measured by dissolution tests in vitro (Beckett and Cowan, I973; Fraser, Leach, and Poston, 1972) .
Differences in biological availability had previously been reported between different brands of digoxin tablets (Manninen, Melin, and Hartel, I97I; Lindenbaum et al., 197I) . We have found that, with some brands of digoxin tablet, crushing the tablet and administering the powder in a capsule gives more rapid absorption and much higher steadystate levels of digoxin (Shaw, Howard, and Hamer, I972) .
In this study we report the steady-state plasma levels of digoxin found during maintenance therapy with Lanoxin tablets made shortly before the recent manufacturing change ('older Lanoxin') and with Lanoxin tablets produced after the change ('newer Lanoxin'). These levels are compared with those Received I2 JUly 1973. recorded in patients using other brands of digoxin tablets. We also report the change in digoxin level seen in a group of patients who used both the older and newer Lanoxin formulations. The dissolution rates of the brands used are given.
The 'Lanoxin' brand of digoxin is manufactured at several centres throughout the world. These results apply to Lanoxin tablets made in the United Kingdom.
Patients and methods Patients
All the patients whose digoxin levels are reported here had normal or near-normal renal function (blood urea < 40 mg/100 ml).
During the period January to mid-June 1972 (i.e. before the newer Lanoxin became available), 73 patients attending a cardiac outpatient clinic had blood taken for plasma digoxin. In the great majority of patients, the blood sample was taken 6 to I0 hours after the last digoxin dose. A few patients had blood taken 5 to 6 or I0 to I8 hours after their last dose. Thirty-eight patients were using Lanoxin tablets and 35 patients used other brands.
Digoxin levels during use of the newer Lanoxin have subsequently been measured in 20 outpatients.
Plasma digoxin was also measured in x2 inpatients who had been on the same daily oral dose of newer Lanoxin for at least one week. In each case the blood sample was taken 6 to I2 hours after the last digoxin dose.
Cross-over group In 13 outpatients and 6 inpatients plasma digoxin levels were measured with both the older and the newer Lanoxin. The outpatients had been told of the importance of taking their tablets regularly and with a constant relation to meals. The inpatients had their drug records checked to ensure that they had been given each dose. The second plasma digoxin estimation was carried out one week after the change. The digoxin levels found with the newer Lanoxin are approximately two-thirds higher than those obtained with the older Lanoxin. The differences at the o025 to o0375 mg/day and o 5 mg/day dosage groups are statistically highly significant (P < o-ooI, t-test). The levels in patients using other brands of digoxin tablets are similar to those found with the older Lanoxin. Cross-over group Table 2 shows the steady state digoxin levels in I9 patients who used the same dose of both the older and newer Lanoxin. The mean level with the older Lanoxin was o-86 ng/ml (SD + o028) and the mean level with the newer Lanoxin I 46 ng/ml (SD + 0o54), an overall increase of 70 per cent. This difference is statistically highly significant (P < oooi, paired t-test).
Changing from older to newer Lanoxin produced an increase in plasma digoxin in each dosage group, but there were striking differences between the groups (Table 3) . Patients in this group using 0-25 tO 0375 mg/day older Lanoxin had a relatively high mean digoxin level of o-87 (SD ± o i8) ng/ml and showed only a moderate increase to II7 (SD ± 0o26) ng/ml on changing to the newer formulation. In the o-5 mg/day dosage group the mean level on older Lanoxin was o'8o (SD ± 0.33) ng/ml and a more pronounced increase to I 52 (SD ± 0o6i) ng/ml was seen when newer Lanoxin was used. The 2 patients in the o075 mg/day group increased from I -I ± 028 tO 2 05 ± o0O7 ng/ml. The digoxin levels found with the newer Lanoxin are similar to those recorded in I969 when patients using Lanoxin were studied by Chamberlain and his co-workers (Chamberlain et al., I970; D. A. Chamberlain, 1972, personal communication) . This is explained by the fact that an initial adjustment of the manufacture of Lanoxin was made in autumn I969 (A. D. Munro-Faure, I972, personal communication). It now appears that the result of this adjustment was to reduce the biological availability of Lanoxin. The recent amendment in the manufacturing process has restored the biological availability of the tablets to their I969 level. The newer Lanoxin seems to produce nearly maximal absorption of the digoxin since the levels obtained with the newer tablets are comparable to those found when tritiated digoxin was given with a daily dosage of a liquid preparation (Marcus et al., I966) .
The range of steady-state plasma levels at which digoxin is usually effective is I to 2 ng/ml. Our results show that most patients with normal or near normal renal function did not achieve a digoxin level greater than I ng/ml when using 0o25 to o 5 mg/day of the older Lanoxin or the average other brand. With the newer Lanoxin, as with the I969 Lanoxin, levels of i tO 2 ng/ml were usually obtained with a daily dosage of 025 to o05 mg/day. We therefore recommend that the newer Lanoxin be used in the traditional dosages of o025-O05 mg/ day for patients of normal size and renal function.
When older Lanoxin was replaced by newer Lanoxin the increase in digoxin level varied considerably from patient to patient. Some patients achieved high levels with older Lanoxin despite its slow dissolution rate; these patients were usually in the o025 mg/day group. Larger differences, up to fourfold, tended to occur in patients who had low levels relative to the dose of older Lanoxin. The range of levels recorded during use of older Lanoxin cannot be wholly explained by differences in body weight and renal function but presumably reflects individual variation in the ability to absorb from slowly dissolving digoxin tablets. When comparing older Lanoxin to other brands we found a similar individual variation, with changes in digoxin level most pronounced in those who were poor digoxin absorbers (Shaw et al., I972) . The findings of Falch, Teien, and Bjerkelund (I973) The existence of digoxin tablets of different and sometimes unknown efficacy continues to cause difficulties in management. Improved precision and safety in digoxin treatment require all digoxin tablets to be of equivalent biological availability. For this to be achieved there is a need for further knowledge of the factors in manufacturing, which influence bioavailability, and new standards for quality control of each batch produced.
